Cooper-deficiency myeloneuropathy in Wilson´s Disease as a result of D-penicillamine treatment: A case report
Objective: To present a case of subacute combined degeneration of the spinal cord secondary to iatrogenic copper deficiency as a result of D-penicillamine therapy. Background:…A case report of Wilson Disease in a Kyrgyz teenager
Objective: Information on the occurrence of WD in the Kyrgyz Republic is currently missing. However, based on previously received epidemiological data to the territories of…Wislon disease: clinical specificities of the disease course under normal ceruloplasmin in the blood, a clinical case from Kyrgyzstan
Objective: Apparent clinical picture of Wilson's disease with normal blood ceruloplasmin levels in young patients with Wilson's disease. Background: Wilson's disease is a hereditary disease…Acquired (non-Wilsonian) hepatocerebral degeneration: case report
Objective: To present a case of the patient with acquired (non-Wilsonian) hepatocerebral degeneration (AHD). Background: AHD is a clinical syndrome which includes movement and cognitive…Neurological Wilson Disease: Clinical Aspects and Evolution in 10 Cases
Objective: Describe the clinical aspects and evolution in 10 patients with neurological Wilson's disease (NWD). Background: Wilson's disease (WD) is a rare autosomal recessive metabolic…Wilson’s disease in Finland
Objective: To investigate the epidemiology and clinical picture of Wilson’s disease (WD) in Finland Background: There are few robust studies on WD epidemiology and none…Structural imaging changes in hepatic and neurological Wilson disease
Objective: To quantitatively assess cerebral structural changes in Wilson disease (WD) subjects with hepatic and neurological phenotypes. Background: WD is a rare autosomal recessive disorder…Contribution of the French registry in the understanding of Wilson disease
Objective: To describe patients from the French Wilson disease (WD) registry. Background: WD is a rare genetic disorder caused by loss of function of the…Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease
Objective: The objective of this study was to characterize neurological manifestations in Wilson Disease (WD) patients and describe specific neurological changes after 24 weeks’ treatment…Explosive flurry of seizures and new-onset cortical-subcortical lesions in a patient with Wilson disease
Objective: We report a patient with stable neurological Wilson disease (WD) who developed repeated seizures and new-onset cortical-subcortical lesions, and discuss the possible causes for…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.